Growth momentum Regenity Biosciences has a multi-decade track record in bioabsorbable regenerative technologies with an expanding product portfolio and recent acquisition of Polyganics, signaling an ongoing growth trajectory and potential for increased contract manufacturing and development collaborations.

Manufacturing footprint With producing operations in Paramus, Oakland and Allendale New Jersey and Groningen Netherlands, Regenity presents a geographically diversified manufacturing base ideal for regional supply agreements, global contract manufacturing, and nearshoring opportunities for medical device companies.

Regenerative focus Specialization in bioabsorbable materials and tissue/bone regeneration positions Regenity as a partner for medtech firms seeking resorbable components, implants, or coating technologies, presenting cross-sell opportunities across multiple device categories.

Scale and readiness Revenue range and employee size indicate a mid-market manufacturing partner capable of handling development-to- commercialization programs, enabling conversations around CDMO/CDD services for mid-sized medical device innovators seeking speed to market.

Strategic partnerships History of contract development and manufacturing, coupled with a broad product line and recent portfolio expansion, suggests opportunities for collaboration on custom resorbable solutions, technology licensing, and joint development programs with device manufacturers expanding regenerative offerings.